ROBERT KRANCE to Antibodies, Monoclonal
This is a "connection" page, showing publications ROBERT KRANCE has written about Antibodies, Monoclonal.
Connection Strength
1.020
-
Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1245-52.
Score: 0.191
-
Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1298-304.
Score: 0.191
-
Successful treatment of bronchiolitis obliterans in a bone marrow transplant patient with tumor necrosis factor-alpha blockade. Pediatrics. 2005 Sep; 116(3):767-70.
Score: 0.153
-
Complement-fixing CD45 monoclonal antibodies to facilitate stem cell transplantation in mouse and man. Ann N Y Acad Sci. 2003 May; 996:80-8.
Score: 0.130
-
Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy. Biol Blood Marrow Transplant. 2003 Apr; 9(4):273-81.
Score: 0.129
-
Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant. 2006 Dec; 12(12):1277-84.
Score: 0.042
-
Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant. 2005 Dec; 36(11):1001-8.
Score: 0.039
-
Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab. Bone Marrow Transplant. 2005 Nov; 36(9):797-802.
Score: 0.039
-
CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors. Bone Marrow Transplant. 2005 Jun; 35(12):1127-32.
Score: 0.038
-
CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000 Feb 15; 95(4):1502-5.
Score: 0.026
-
Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1. Lancet. 1995 Sep 23; 346(8978):805-6.
Score: 0.019
-
XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors. Bone Marrow Transplant. 1994 May; 13(5):571-5.
Score: 0.017
-
Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. Blood. 1992 Dec 15; 80(12):3182-8.
Score: 0.004
-
Peripheral T cell lymphoma: immunologic and cell-kinetic observations associated with morphological progression. Blood. 1985 Oct; 66(4):980-9.
Score: 0.002